Company Growth (employees)
Foundation Medicine was founded in 2010 and is headquartered in Cambridge, US
Key People at Foundation Medicine
Michael J. Pellini
President & CEO & Board Director
Steven J. Kafka
Chief Business Officer
Alexis Borisy
Co - Founder & Chairman of the Board
Vincent A. Miller
SVP, Clinical Development
Foundation Medicine Office Locations
Foundation Medicine has an office in Cambridge
Cambridge, US (HQ)
150 Second St
Foundation Medicine Data and Metrics
Foundation Medicine Financial Metrics
Foundation Medicine's revenue was reported to be $16.7 m in Q1, 2017
USD
Revenue (Q1, 2017) | 16.7 m |
Gross profit (Q1, 2017) | (436 k) |
Gross profit margin (Q1, 2017), % | (3%) |
Net income (Q1, 2017) | (46.5 m) |
EBIT (Q1, 2017) | (46.7 m) |
Market capitalization (21-Sep-2017) | 1.4 b |
Cash (31-Mar-2017) | 49.1 m |
Foundation Medicine's current market capitalization is $1.4 b.
- Source: SEC Filings
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 29 m | 61.1 m | 93.2 m | 116.9 m |
Revenue growth, % | 111% | 53% | 25% | |
Cost of goods sold | 11.7 m | 27.4 m | 36.7 m | 53 m |
Gross profit | 17.3 m | 33.6 m | 56.5 m | 63.9 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 14.5 m | 16.4 m | 19.3 m | 18.3 m | 21 m | 17.4 m | 20.7 m | 16.3 m | 16.7 m |
Cost of goods sold | 6.6 m | 7.5 m | 8.9 m | 9 m | 9.1 m | 10 m | 11.5 m | 14.7 m | 17.1 m |
Gross profit | 7.9 m | 8.9 m | 10.4 m | 9.4 m | 11.9 m | 7.4 m | 9.2 m | 1.6 m | (436 k) |
Gross profit Margin, % | 54% | 54% | 54% | 51% | 57% | 42% | 45% | 10% | (3%) |
- Source: SEC Filings
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 124.3 m | 72.1 m | 117.8 m | 63.6 m |
Accounts Receivable | 6.3 m | 9.9 m | 7.4 m | 8.2 m |
Inventories | 992 k | 2.9 m | 6.5 m | 10.4 m |
Current Assets | 133.3 m | 89.6 m | 229.6 m | 168.9 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 97.1 m | 86.7 m | 61.7 m | 263.6 m | 250.2 m | 86.1 m | 62.3 m | 77.8 m | 49.1 m |
Accounts Receivable | 6.1 m | 6 m | 10.7 m | 5.9 m | |||||
Inventories | 2.6 m | 4.2 m | 4.5 m | 6.1 m | 9.5 m | 6.7 m | 10.2 m | 12 m | 10.3 m |
Current Assets | 106.9 m | 98.3 m | 80.8 m | 289.5 m | 275.8 m | 235.9 m | 216.8 m | 196.5 m | 125.5 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (42.9 m) | (52.2 m) | (89.6 m) | (113.2 m) |
Depreciation and Amortization | 5 m | 8.2 m | 10.6 m | 15.9 m |
Accounts Receivable | (4.1 m) | (3.6 m) | 2.4 m | (844 k) |
Inventories | (442 k) | (1.9 m) | (3.7 m) | (2.4 m) |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (13.8 m) | (13 m) | (17 m) | (33.1 m) | (20.6 m) | (17.3 m) | (29 m) | (31.3 m) | (46.5 m) |
Accounts Receivable | 6.1 m | 6 m | 10.7 m | 5.9 m | |||||
Inventories | 2.6 m | 4.2 m | 4.5 m | 6.1 m | 9.5 m | 6.7 m | 10.2 m | 12 m | 10.3 m |
Accounts Payable | 5.5 m | 5.5 m | 9.4 m | 9.4 m | 12 m | 8.5 m | 10.8 m | 12 m | 10.4 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 31.2 k |
Financial Leverage | 1.3 x |
Foundation Medicine Operating Metrics
Foundation Medicine's Customers was reported to be 30 in FY, 2016
| FY, 2016 | |
|---|---|
Products | 5 |
Customers | 30 |
Facilities | 4 |
Foundation Medicine Market Value History
Foundation Medicine Revenue Breakdown
Foundation Medicine Median Salaries
Source: 15 public H-1B filings from Foundation Medicine
Market Position of Foundation Medicine
Traffic Overview of Foundation Medicine
Foundation Medicine Online and Social Media Presence
Foundation Medicine News and Updates
September 08, 2017
Investors including Google Ventures poured $93 million into a company that's building personalized cancer vaccines
A biotech company that's developing personalized cancer treatments just raised $93 million to get their drugs into human trials.
Gritstone Oncology is working on a type of cancer immunotherapy called cancer vaccines that seeks to help amplify the body's immune system to fig…
March 31, 2017
GV’s Tom Hulme on AI, life sciences, and Alphabet VC’s future in Europe
GV — the VC owned by Google’s Alphabet and formerly known as Google Ventures — has had a few ups and downs in Europe since first setting up its stall here in London in 2014. It initially stormed into the market with $125 million to invest in its first year, along with four permanent partners (Tom H…
January 24, 2017
There's now a genetic test for women's fertility called Fertilome
It seems these days that there's a DNA test for everything — from your wine preferences to testing for what "superhero" genetic variants you might have.
And for those interested in seeing how that genetic information could inform their health, the field is starting to expand…
January 23, 2017
Seven Bridges to Present on Cancer Moonshot’s Blood Profiling Atlas at Precision Medicine World Congress
PRESS RELEASE: Seven Bridges, the biomedical data analysis company, today announced that its Senior VP of Commercial Operations, Bruce Press, will join Dr. Howard Scher of Memorial Sloan Kettering Cancer Center and Dr. Geoff Otto of Foundation...
December 15, 2016
Boston Millennia Partners Invests in Cota, Inc.
PRESS RELEASE: Boston Millennia Partners is pleased to announce its investment in Cota, Inc. as part of an $18 million growth equity round. Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification...
December 05, 2016
Google Ventures’ Founder Is Raising $230 Million for a New Health Care Fund
The details are still scarce.